US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

Qiagen N.V. Common Shares (NY:QGEN)

45.31 -0.07 (-0.15%)
Official Closing Price Updated: 7:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
QIAGEN Reports Full Results for Q1 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >